These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9863713)

  • 21. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II.
    Kawaguchi A; Miyao Y; Noguchi T; Nonogi H; Yamagishi M; Miyatake K; Kamikubo Y; Kumeda K; Tsushima M; Yamamoto A; Kato H
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):251-8. PubMed ID: 10634826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy.
    Hansen JB; Sandset PM
    Thromb Res; 1998 Aug; 91(4):177-81. PubMed ID: 9736420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterogeneity of plasma tissue factor pathway inhibitor.
    Broze GJ; Lange GW; Duffin KL; MacPhail L
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):551-9. PubMed ID: 7841311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man.
    Hansen JB; Sandset PM; Huseby KR; Huseby NE; Nordøy A
    Thromb Haemost; 1996 Nov; 76(5):703-9. PubMed ID: 8950777
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.
    Harris GM; Stendt CL; Vollenhoven BJ; Gan TE; Tipping PG
    Am J Hematol; 1999 Mar; 60(3):175-80. PubMed ID: 10072106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.
    Alban S; Gastpar R
    Thromb Haemost; 2001 May; 85(5):824-9. PubMed ID: 11372675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effects of LDL-associated tissue factor pathway inhibitor.
    Augustsson C; Hilden I; Petersen LC
    Thromb Res; 2014 Jul; 134(1):132-7. PubMed ID: 24787991
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI.
    Kokawa T; Enjyoji K; Kumeda K; Kamikubo Y; Harada-Shiba M; Koh H; Tsushima M; Yamamoto A; Kato H
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):802-8. PubMed ID: 8640408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue factor pathway inhibitor (TFPI)--an update.
    Sandset PM
    Haemostasis; 1996 Oct; 26 Suppl 4():154-65. PubMed ID: 8979119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of protamine sulphate on plasma tissue factor pathway inhibitor released by intravenous and subcutaneous unfractionated and low molecular weight heparin in man.
    Holst J; Lindblad B; Bergqvist D; Hedner U; Nordfang O; Ostergaard P
    Thromb Res; 1997 May; 86(4):343-8. PubMed ID: 9187023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levels of heparin-releasable TFPI are increased in first-ever lacunar stroke patients.
    Knottnerus IL; Winckers K; Ten Cate H; Hackeng TM; Lodder J; Rouhl RP; Staals J; Govers-Riemslag JW; Bekers O; van Oostenbrugge RJ
    Neurology; 2012 Feb; 78(7):493-8. PubMed ID: 22302552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A supersulfated low-molecular-weight heparin (IK-SSH) increases plasma levels of free and total tissue factor pathway inhibitor after intravenous and subcutaneous administration in humans.
    Kaiser B; Glusa E; Hoppensteadt DA; Breddin HK; Amiral J; Fareed J
    Blood Coagul Fibrinolysis; 1998 Sep; 9(6):517-23. PubMed ID: 9819002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI).
    Xu X; Takano R; Nagai Y; Yanagida T; Kamei K; Kato H; Kamikubo Y; Nakahara Y; Kumeda K; Hara S
    Int J Biol Macromol; 2002 Jun; 30(3-4):151-60. PubMed ID: 12063117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of tissue factor pathway inhibitor in the coronary circulation of patients with acute coronary syndromes.
    Golino P; Ravera A; Ragni M; Cirillo P; Piro O; Chiariello M
    Circulation; 2003 Dec; 108(23):2864-9. PubMed ID: 14656922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
    Mukherjee M; Ranlall N; Patel G; Rutlin A; Jehanli A; Kakkar VV
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations.
    Jeske W; Hoppensteadt D; Fareed J; Bermes E
    Blood Coagul Fibrinolysis; 1995 Jun; 6 Suppl 1():S73-80. PubMed ID: 7647226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
    Ariëns RA; Alberio G; Moia M; Mannucci PM
    Thromb Haemost; 1999 Feb; 81(2):203-7. PubMed ID: 10063992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.
    Altman R; Scazziota A; Rouvier J
    Haemostasis; 1998; 28(5):229-35. PubMed ID: 10420071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI).
    Dahm AE; Andersen TO; Rosendaal F; Sandset PM
    J Thromb Haemost; 2005 Apr; 3(4):651-8. PubMed ID: 15842349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
    Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.